Impact of Tixel Treatment on Symptoms and Signs in Patients with Dry Eye Disease

Last updated: September 24, 2024
Sponsor: Aston University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sjogren's Syndrome

Dry Eyes

Dry Eye Disease

Treatment

Sham treatment

Thermo-mechanical action based peri-orbital fractional skin treatment

Clinical Study ID

NCT06615453
HLS21162
RECID HLS21162
  • Ages > 18
  • All Genders

Study Summary

This study will examine how a standard Tixel treatment versus a sham treatment for eye wrinkles affects the symptoms and signs of Dry Eye Disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Mild to Moderate Periorbital wrinkles

  2. OSDI score of at least 23

  3. Noninvasive Tear film break up time (NIBUT) ≤ 10 seconds

  4. No other eye or skin or immune problems

  5. Willing and able to provide written informed consent.

  6. Willing to participate in all study activities and instructions.

Exclusion

Exclusion Criteria:

  1. Pregnancy and/or breastfeeding

  2. Lesions in the periorbital area

  3. Acute severe blepharitis

  4. Acute conjunctivitis

  5. Use of eye drops within 2 hours before examination

  6. Other concomitant anterior eye disease

  7. Has undergone outdoors/sunbed tanning during the last 4 weeks

  8. Is unwilling to follow the Tixel aftercare instructions after each of the threeTixel treatments.

  9. Active Herpes Simplex or tendency for Herpes Simplex in the periorbital area (meaning the subject has had the condition previously).

  10. Current skin cancer, malignant sites and/or advanced premalignant lesions or molesin the treatment area.

  11. An impaired immune system condition or use of immunosuppressive medication.

  12. Collagen disorders, keloid formation and/or abnormal wound healing.

  13. Previous invasive/ablative procedures in the areas to be treated within 3 monthsprior to initial treatment or plans for such treatment during the course of theTixel2 device treatment, or before complete healing of such treatments has occurred.

  14. Any patient who takes or has taken any medications (including via topicalapplication), herbal treatment (oral or topic), food supplements or vitamins, whichmay cause fragile skin or impaired skin healing during the last 3 months.

  15. Any patient who has used oral Isotretinoin (Accutane® or Roaccutan®) within 3 monthsprior to treatment or less.

  16. Any patient who has a history of bleeding coagulopathies or use of anticoagulants.

  17. Any patient who has tattoos or permanent makeup in the treated area.

  18. Any patient who has burned skin, blistered skin, irritated skin, or sensitive skinin any of the areas to be treated.

  19. Any patient who underwent thread lifting of the area to be treated in the last 3months.

Study Design

Total Participants: 36
Treatment Group(s): 2
Primary Treatment: Sham treatment
Phase:
Study Start date:
September 17, 2024
Estimated Completion Date:
September 30, 2025

Connect with a study center

  • Vision Science, School of Optometry

    Birmingham, B4 7ET
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.